Stock Events

Acadia Pharmaceuticals 

$25.13
0
+$0+0% Friday 17:11

Statistics

Day High
25.13
Day Low
24.93
52W High
33.96
52W Low
17.83
Volume
140
Avg. Volume
2,000
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27FebConfirmed
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-0.43
-0.19
0.06
0.3
Expected EPS
0.3
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0A4W.LSE. It's not an investment recommendation.

About

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Show more...
CEO
Mr. Stephen R. Davis J.D.
Employees
510
Country
United States
ISIN
US0042251084
WKN
000603035

Listings